Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04032717 · ClinicalTrials.gov registry record · Phase 1
Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)
A Phase 1 study, sponsored by Rhonda Brand.
- Terminated
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT04032717 is a Phase 1 study that was terminated before completion, run by Rhonda Brand. The registered enrollment target is 18 participants.
The verdict
NCT04032717, a Phase 1 study, was terminated before completion, sponsored by Rhonda Brand.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is the first-in-human clinical study to see if a single dose of an investigational enema made from a modified plant protein called Q-Griffithsin is safe, tolerated, and acceptable for use by healthy adults 18-45 years of age who practice receptive anal intercourse.
Interventions
- DRUG Q-Griffithsin (Q-GRFT) enema
- OTHER Placebo enema
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2019-07-10 |
| Est. Completion | 2021-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04032717
The ClinicalTrials.gov registry entry for NCT04032717 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rhonda Brand, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Q-Griffithsin (Q-GRFT) enema is the first listed.
NCT04032717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04032717 about?
NCT04032717 is a clinical study titled "Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)". This is the first-in-human clinical study to see if a single dose of an investigational enema made from a modified plant protein called Q-Griffithsin is safe, tolerated, and acceptable for use by healthy adults 18-45 years of age who practice receptive anal intercourse.
What is the current status of trial NCT04032717?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2019-07-10. Estimated completion is 2021-02-04.
What interventions are being tested in trial NCT04032717?
The interventions under investigation include: Q-Griffithsin (Q-GRFT) enema (DRUG), Placebo enema (OTHER).
Who is sponsoring clinical trial NCT04032717?
This trial is sponsored by Rhonda Brand, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.